Immunomodulation after locoregional anti-tumoral treatment

US11723956B2 · kind B2 · utility

Assignees

• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• UNIVERSITÉ PARIS CITÉ · FR
• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
• ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS · FR
• Universite de Versailles Saint-Quentin-en-Yvelines · FR

Inventors

• Robert Malafosse · Paris, FR
• Nathalie Mignet · Paris, FR
• Vincent Boudy · Paris, FR
• Johanne Seguin · Crouy-sur-Cosson, FR
• Kathia Lemdani · Paris, FR
• Claude Capron · Boulogne, FR

Key dates

• Filing date: Aug 31, 2017
• Grant date: Aug 15, 2023
• Expiry date: Aug 31, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.